A study has suggested that a potential US-UK medicine deal could have severe consequences for the UK's national health service, potentially leading to a significant number of excess deaths. However, not all outlets agree on the impact of the deal, with some arguing that it will benefit patients. The deal's effects on the NHS and the pharmaceutical industry are a subject of controversy and debate.